Advances in Colloid and Interface Science,
Journal Year:
2024,
Volume and Issue:
329, P. 103200 - 103200
Published: May 21, 2024
Age-related
macular
degeneration
(AMD)
is
a
leading
cause
of
vision
loss
in
the
elderly.
The
current
standard
treatment
for
AMD
involves
frequent
intravitreal
administrations
therapeutic
agents.
While
effective,
this
approach
presents
challenges,
including
patient
discomfort,
inconvenience,
and
risk
adverse
complications.
Nanoparticle-based
drug
delivery
platforms
offer
promising
solution
to
overcome
these
limitations.
These
are
engineered
target
retina
specifically
control
release,
which
enhances
retention,
improves
concentration
bioavailability
at
retinal
site,
reduces
frequency
injections.
This
review
aims
uncover
design
principles
guiding
development
highly
effective
nanoparticle-based
treatment.
By
gaining
deeper
understanding
physiology
ocular
barriers
physicochemical
properties
nanoparticles,
we
establish
basis
designing
nanoparticles
optimize
retention
retina.
Furthermore,
recent
strategies
highlight
their
potential
improving
efficiency.
Lastly,
address
challenges
opportunities
field,
providing
insights
into
future
improve
outcomes
patients.
ACS Applied Bio Materials,
Journal Year:
2024,
Volume and Issue:
7(4), P. 2070 - 2085
Published: March 15, 2024
Retinal
diseases,
such
as
age-related
macular
degeneration,
diabetic
retinopathy,
and
retinoblastoma,
stand
the
leading
causes
of
irreversible
vision
impairment
blindness
worldwide.
Effectively
administering
drugs
for
retinal
diseases
poses
a
formidable
challenge
due
to
presence
complex
ocular
barriers
elimination
mechanisms.
Over
time,
various
approaches
have
been
developed
fabricate
drug
delivery
systems
improving
therapy
including
virus
vectors,
lipid
nanoparticles,
polymers.
However,
conventional
nanocarriers
encounter
issues
related
controllability,
efficiency,
safety
in
retina.
Therefore,
development
smart
effective
or
more
invasive
long-term
treatment
remains
desirable
goal.
Recently,
surfaced
intelligent
design
nanocarriers,
leveraging
specific
responses
external
internal
triggers
enabling
multiple
functions
topical
administration,
prolonged
release,
site-specific
delivery.
This
Review
provides
an
overview
prevalent
pathologies
pharmacotherapies
enhance
understanding
diseases.
It
also
surveys
recent
developments
strategies
employed
disease.
Finally,
challenges
potential
clinical
therapeutic
applications
are
discussed
inspire
next
generation
nanocarriers.
Journal of Nanobiotechnology,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: March 1, 2023
Sustained
retina
drug
delivery
and
rational
combination
are
considered
essential
for
enhancing
the
efficacy
of
therapy
wet
age-related
macular
degeneration
(wAMD)
due
to
conservative
structure
posterior
ocular
segment
multi-factorial
pathological
mechanism.
Designing
a
co-delivery
system
that
can
simultaneously
achieve
deep
penetration
long-lasting
retention
in
vitreous
is
highly
desired,
yet
remains
huge
challenge.
In
this
study,
we
fabricated
Bor/RB-M@TRG
as
an
intravitreal-injectable
hydrogel
depot
into
distribution
retinal
pigment
epithelium
(RPE)
layer.
The
consisted
borneol-decorated
rhein
baicalein-coloaded
microemulsions
(Bor/RB-M,
entity)
temperature-responsive
matrix
(the
intravitreal
depot).
Bor/RB-M
exhibited
strongest
vitro
anti-angiogenic
effects
among
all
groups
studied,
which
potentially
associated
with
improved
cellular
uptake,
well
synergism
baicalein,
acting
via
anti-oxidative
stress
pathways,
respectively.
Importantly,
single
(IVT)
injection
displayed
significant
inhibition
against
CNV
wAMD
model
mice,
compared
other
groups.
Particularly,
coumarin-6-labeled
(Bor/C6-M@TRG)
could
not
only
deeply
penetrate
but
also
stably
accumulate
RPE
layer
at
least
14
days.
Our
design
integrates
advantages
depots,
offering
promising
new
approach
clinically-translatable
synergistic
anti-wAMD
treatment.
Advanced Healthcare Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 13, 2024
Nanozymes,
characterized
by
their
nanoscale
size
and
enzyme-like
catalytic
activities,
exhibit
diverse
therapeutic
potentials,
including
anti-oxidative,
anti-inflammatory,
anti-microbial,
anti-angiogenic
effects.
These
properties
make
them
highly
valuable
in
nanomedicine,
particularly
ocular
therapy,
bypassing
the
need
for
systemic
delivery.
Nanozymes
show
significant
promise
tackling
multi-factored
diseases,
those
influenced
oxidation
inflammation,
like
dry
eye
disease,
age-related
macular
degeneration.
Their
small
size,
coupled
with
ease
of
modification
integration
into
soft
materials,
facilitates
effective
penetration
barriers,
thereby
enabling
targeted
or
prolonged
therapy
within
eye.
This
review
is
dedicated
to
exploring
diseases
that
are
intricately
linked
shedding
light
on
role
nanozymes
managing
these
conditions.
Additionally,
recent
studies
elucidating
advanced
applications
therapeutics,
along
materials
disease
management,
discussed.
Finally,
this
outlines
directions
future
investigations
aimed
at
bridging
gap
between
nanozyme
research
clinical
applications.
Advances in Colloid and Interface Science,
Journal Year:
2024,
Volume and Issue:
329, P. 103200 - 103200
Published: May 21, 2024
Age-related
macular
degeneration
(AMD)
is
a
leading
cause
of
vision
loss
in
the
elderly.
The
current
standard
treatment
for
AMD
involves
frequent
intravitreal
administrations
therapeutic
agents.
While
effective,
this
approach
presents
challenges,
including
patient
discomfort,
inconvenience,
and
risk
adverse
complications.
Nanoparticle-based
drug
delivery
platforms
offer
promising
solution
to
overcome
these
limitations.
These
are
engineered
target
retina
specifically
control
release,
which
enhances
retention,
improves
concentration
bioavailability
at
retinal
site,
reduces
frequency
injections.
This
review
aims
uncover
design
principles
guiding
development
highly
effective
nanoparticle-based
treatment.
By
gaining
deeper
understanding
physiology
ocular
barriers
physicochemical
properties
nanoparticles,
we
establish
basis
designing
nanoparticles
optimize
retention
retina.
Furthermore,
recent
strategies
highlight
their
potential
improving
efficiency.
Lastly,
address
challenges
opportunities
field,
providing
insights
into
future
improve
outcomes
patients.
